Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Antonio Rueda, David Olmos, Luis Vicioso, Cristina Quero, Elena Gallego, Bella Isabel Pajares-Hachero, Marta Mendiola, María Casanova, Martina Álvarez, Mariano Provencio & Emilio Alba. (2015) Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. Leukemia & Lymphoma 56:5, pages 1286-1294.
Read now
Read now
Antonio Rueda, Julio Rifá, Cristina Quero, José Gómez-Codina, Adolfo Murias, Francisco Ramón García-Arroyo, Pilar Sabín, Marta Llanos, Joaquin Herrero, Francisco Lobo, Juan Ramón Delgado & Mariano Provencio. (2014) High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma. Leukemia & Lymphoma 55:6, pages 1413-1416.
Read now
Read now
Georgios S. Dimtsas, Eleni C. Georgiadi, Petros Karakitsos, Theodoros P. Vassilakopoulos, Irene Thymara, Penelope Korkolopoulou, Efstratios Patsouris, Christos Kittas & Ipatia A. Doussis-Anagnostopoulou. (2014) Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leukemia & Lymphoma 55:3, pages 558-564.
Read now
Read now
Ranjana H. Advani, Fangxin Hong, Sandra J. Horning, Brad S. Kahl, Judith Manola, Lode J. Swinnen, Thomas M. Habermann & Kristen Ganjoo. (2012) Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leukemia & Lymphoma 53:4, pages 718-720.
Read now
Read now
Maria B. Karpova, Kazuyasu Fujii, Daniella Jenni, Reinhard Dummer & Mirjana Urosevic-Maiwald. (2011) Evaluation of lymphangiogenic markers in Sézary syndrome. Leukemia & Lymphoma 52:3, pages 491-501.
Read now
Read now
Handan Ugur Dincaslan, Gulsan Yavuz, Emel Unal, Nurdan Tacyildiz, Aydan Ikinciogullari, Figen Dogu, Deniz Guloglu, Nazmiye Yuksek & Ulya Ertem. (2010) DOES SERUM SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS HAVE DIFFERENT IMPORTANCE IN PEDIATRIC ACUTE LEUKEMIA AND MALIGNANT LYMPHOMA PATIENTS?. Pediatric Hematology and Oncology 27:7, pages 503-516.
Read now
Read now
Ana Paula de Souza & Cristina Bonorino. (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Review of Anticancer Therapy 9:9, pages 1317-1332.
Read now
Read now
Dita Gratzinger. (2009) VEGF-C: putting the ‘lymph’ back in lymphoma?. Leukemia & Lymphoma 50:3, pages 311-312.
Read now
Read now
Articles from other publishers (16)
Dominic Kaddu‐Mulindwa, Maciej Rosolowski, Marita Ziepert, Evi Regitz, Gunter Assmann, Moritz Bewarder, Gerhard Held, Michael Pfreundschuh & Jörg Thomas Bittenbring. (2020) VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma. European Journal of Haematology 106:1, pages 100-104.
Crossref
Crossref
Lutz Menzel, Uta E. Höpken & Armin Rehm. (2020) Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Frontiers in Immunology 11.
Crossref
Crossref
Orsolya Matolay & Gábor Méhes. (2019) Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia. Frontiers in Oncology 9.
Crossref
Crossref
Chieh-Lung Cheng, Yung-Cheng Su, Tsu-Yi Chao, Chung-Wu Lin, Sheng-Chieh Chou, Ming Yao, Sung-Hsin Kuo & Shan-Chi Yu. (2018) Intralymphatic Spread is a Rare Finding Associated With Poor Prognosis in Diffuse Large B-Cell Lymphoma With Extranodal Involvements. American Journal of Surgical Pathology 42:5, pages 616-624.
Crossref
Crossref
W.J. Lee, Y.J. Kim, Y.J. Lee, C.H. Won, S.E. Chang, J.H. Choi & M.W. Lee. (2017) Vascular endothelial growth factor protein expression is associated with a poor prognosis in patients with cutaneous extranodal natural killer/T‐cell lymphoma. British Journal of Dermatology 178:1.
Crossref
Crossref
Antica Duletić-Načinović, Vedrana Gačić, Toni Valković, Ksenija Lučin, Elizabeta Fišić, Marta Žuvić-Butorac, Irena Seili-Bekafigo & Nives Jonjić. (2016) Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica 136:1, pages 52-61.
Crossref
Crossref
Jing Yang, Wenlu Li, Xin He, Guofei Zhang, Lan Yue & Ying Chai. (2015) VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis. Disease Markers 2015, pages 1-9.
Crossref
Crossref
Carlos Aya-Bonilla, Emily Camilleri, Larisa M Haupt, Rod Lea, Maher K Gandhi & Lyn R Griffiths. (2014) In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL). BMC Genomics 15:1.
Crossref
Crossref
Ewa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, Anne-Sophie Michallet, Krzysztof Warzocha, Przemysław Biliński, Peter Boyle, Bertrand Coiffier & Gilles Salles. (2013) Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. Archivum Immunologiae et Therapiae Experimentalis 61:2, pages 165-174.
Crossref
Crossref
Tomasz Wróbel, Grzegorz Mazur, Justyna Dzietczenia, Katarzyna Gębura, Kazimierz Kuliczkowski & Katarzyna Bogunia-Kubik. (2013)
VEGF
and
bFGF
Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma
. BioMed Research International 2013, pages 1-6.
Crossref
Crossref
Sahar F.M. Mansour & Hala A.D. Mohamed. (2012) The prognostic impact of microvessel density using angiogenic markers (CD105 and CD34) on patients with diffuse large B-cell lymphoma. Egyptian Journal of Pathology 32:2, pages 268-273.
Crossref
Crossref
Julian Paesler, Iris Gehrke, Simon Jonas Poll-Wolbeck & Karl-Anton Kreuzer. (2012) Targeting the vascular endothelial growth factor in hematologic malignancies. European Journal of Haematology 89:5, pages 373-384.
Crossref
Crossref
SHU-PEI MA, MEI LIN, HAI-NING LIU & JIAN-XIAN YU. (2012) Lymphangiogenesis in non-Hodgkin’s lymphoma and its correlation with cyclooxygenase-2 and vascular endothelial growth factor-C. Oncology Letters 4:4, pages 695-700.
Crossref
Crossref
B. Wolfesberger, Z. Tonar, A. Fuchs-Baumgartinger, I. Walter, M. Skalicky, K. Witter, J.G. Thalhammer, M. Pagitz & M. Kleiter. (2012) Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs. Research in Veterinary Science 92:3, pages 444-450.
Crossref
Crossref
Wosztyl Anna, Wołowiec Dariusz, Ziółkowska Ewelina, Robak Ewa & Korycka-Wołowiec Anna. (2012) Osoczowe stężenie cytokin limfo-i angiogennych u chorych na chłoniaka rozlanego z dużych komórek B. Acta Haematologica Polonica 43:3, pages 277-284.
Crossref
Crossref
Berber D. Roorda, Arja ter Elst, Frank J.G. Scherpen, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps & Eveline S.J.M. de Bont. (2010) VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27KIP1 via paracrine mechanisms. European Journal of Cancer 46:5, pages 974-982.
Crossref
Crossref